Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s share price fell 5.6% during mid-day trading on Friday . The company traded as low as $2.81 and last traded at $2.84. 555,974 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 737,581 shares. The stock had previously closed at $3.01.
Analysts Set New Price Targets
A number of brokerages recently commented on CURLF. Needham & Company LLC reiterated a "buy" rating and issued a $6.25 target price on shares of Curaleaf in a research report on Thursday, August 8th. Cormark raised Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Monday, August 12th.
View Our Latest Report on CURLF
Curaleaf Stock Performance
The company's 50-day moving average price is $3.56 and its 200 day moving average price is $4.42. The stock has a market capitalization of $1.84 billion, a PE ratio of -7.28 and a beta of 0.83. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.50 and a current ratio of 1.09.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.75% and a negative net margin of 18.59%. The company had revenue of $342.29 million during the quarter, compared to analysts' expectations of $344.57 million. On average, equities research analysts expect that Curaleaf Holdings, Inc. will post -0.23 earnings per share for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
